BHC

Business Context and Reporting Period

Company: Bausch Health Companies Inc.
Filing Type: Form 10-Q (Unaudited)
Period Ended: March 31, 2025
Business Overview: A global, diversified specialty pharmaceutical and medical device company operating in gastroenterology, hepatology, neurology, dermatology, and eye health (via an 88% ownership of Bausch + Lomb). The company is actively pursuing the separation of its Bausch + Lomb eye health business, contingent on debt leverage targets and regulatory approvals.

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue Growth: Revenues increased 5% ($106 million) year-over-year, driven by higher volumes and improved net pricing in the Salix, Bausch + Lomb, and Solta Medical segments. This was partially offset by unfavorable foreign currency impacts ($37 million).
• Operating Income: Decreased slightly by $5 million to $276 million. While contribution margins improved, this was offset by a $73 million increase in Selling, General, and Administrative (SG&A) expenses (primarily due to MIEBO marketing) and a $15 million increase in "Other expense, net" (driven by $28 million in acquired in-process R&D costs for the Whitecap Biosciences acquisition).
• Segment Performance:
  • Salix: Revenue up 9% and profit up 13%.
  • Solta Medical: Revenue up 28% and profit up 33%.
  • Bausch + Lomb: Revenue up 3%, but segment profit declined 26% ($62 million) due to increased selling expenses and a $15 million inventory reserve charge related to a voluntary recall of enVista IOL products.
• Interest Expense: Decreased by $25 million to $330 million, attributed to debt repurchases and lower outstanding balances on the AR Credit Facility.

Guidance, Outlook, and Material Events

Subsequent Event: April 2025 Refinancing

On April 8, 2025, the company closed a major refinancing transaction to extend debt maturities and reduce near-term cash requirements:

• New Debt: Issued $4.4 billion in 10.00% Senior Secured Notes due 2032 and entered into a new credit agreement providing a $500 million revolving facility and a $3.0 billion term loan (both due 2030).
• Redemptions: Used proceeds to repay approximately $6.87 billion in existing debt, including the February 2027 Term Loan B and various senior secured and unsecured notes maturing between 2025 and 2028.
• Impact: This transaction significantly reduces debt maturities in the remainder of 2025 and 2026, providing greater operational flexibility.

Outlook and Risks

• B+L Separation: The company continues to evaluate the separation of Bausch + Lomb. Completion is subject to achieving targeted debt leverage ratios and shareholder approvals. The recent refinancing supports the capital structure required for this separation.
• Product Recall: Bausch + Lomb completed an investigation into the voluntary recall of enVista IOL products, identifying a raw material issue. Production has resumed, and the company expects to return to full market supply in the U.S. in the coming weeks.
• Legal Proceedings: Significant ongoing litigation includes the Xifaxan Generics Litigation (patent disputes with multiple generic manufacturers) and securities opt-out actions. The company has accrued $310 million for probable and reasonably estimable legal contingencies.
• Healthcare Reform: Xifaxan was selected by CMS for the Medicare drug price negotiation program, with initial price applicability in 2027, which may accelerate revenue erosion.

Investor Verification Checklist

• Debt Covenant Compliance: Verify the company's ability to maintain the "Blended First Lien Leverage Ratio" and minimum liquidity covenants under the new 2025 Credit Agreement, particularly given the high interest expense environment.
• Xifaxan Patent Status: Monitor the status of the Xifaxan Generics Litigation, as a loss could trigger significant revenue declines and potential impairment of intangible assets (carrying value ~$1.48 billion).
• B+L Separation Timeline: Assess the likelihood and timing of the Bausch + Lomb separation, as this is a primary strategic objective for unlocking value and managing capital structure.
• enVista Recall Impact: Track the financial impact of the enVista IOL recall on Bausch + Lomb's future revenues and any potential product liability claims.
• Refinancing Terms: Review the specific terms of the April 2025 refinancing, including the 100% net cash proceeds sweep on the sale of Bausch + Lomb shares, which restricts the monetization of the B+L stake.